Literature DB >> 31079956

Accuracy in risk understanding among BRCA1/2-mutation carriers.

Dorothee Speiser1, Felix G Rebitschek2, Markus A Feufel3, Hannah Brand4, Laura Besch4, Friederike Kendel5.   

Abstract

OBJECTIVE: BRCA1/2-mutation carriers are at high risk of developing cancer. Since they must weigh clinical recommendations and decide on risk-reducing measures, the correct understanding of their 10-year cancer risks is essential. This study focused on the accuracy of women's subjective estimates of developing breast and ovarian cancer within ten years as prerequisite to reduce unnecessary prevention.
METHODS: 59 and 52 BRCA1/2-mutation carriers provided their individual risks of developing breast or ovarian cancer in the next 10 years, along with self-reported sociodemographic and psychosocial variables. Women's risk estimates were compared with their objective cancer risks that had been communicated before.
RESULTS: 22.6% of counselees under- and 53.2% of the counselees overestimated their 10-year risk of developing breast cancer. As for ovarian cancer, 5.6% under- whereas 51.9% overestimated their risk. Neither demographic factors such as education, parenthood and age, nor a prior diagnosis of breast cancer or prophylactic surgery accounted for these variations in risk accuracy.
CONCLUSION: Currently, risk communication during genetic counseling does not guarantee accurate risk estimation in BRCA-mutation carriers. PRACTICE IMPLICATIONS: Counselors must be prepared to prevent overestimation. Counselees' risk estimates need to be assessed and corrected to enable informed decision-making and reduce risks of unnecessary preventive efforts.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BRCA1/2 gene mutation; Genetic counseling; Risk accuracy; Risk perception; Subjective risk estimation

Mesh:

Year:  2019        PMID: 31079956     DOI: 10.1016/j.pec.2019.05.007

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  6 in total

1.  Accuracy of Perceived Breast Cancer Risk in Black and White Women with an Elevated Risk.

Authors:  Jessica M L Young; Kristen J Vogel Postula; Debra Duquette; Melissa Gutierrez-Kapheim; Vivian Pan; Maria C Katapodi
Journal:  Ethn Dis       Date:  2022-04-21       Impact factor: 2.006

2.  Breast MRI texture analysis for prediction of BRCA-associated genetic risk.

Authors:  Georgia Vasileiou; Maria J Costa; Christopher Long; Iris R Wetzler; Juliane Hoyer; Cornelia Kraus; Bernt Popp; Julius Emons; Marius Wunderle; Evelyn Wenkel; Michael Uder; Matthias W Beckmann; Sebastian M Jud; Peter A Fasching; Alexander Cavallaro; André Reis; Matthias Hammon
Journal:  BMC Med Imaging       Date:  2020-07-29       Impact factor: 1.930

3.  Do Preferred Risk Formats Lead to Better Understanding? A Multicenter Controlled Trial on Communicating Familial Breast Cancer Risks Using Different Risk Formats.

Authors:  Lidewij Henneman; Christi J van Asperen; Jan C Oosterwijk; Fred H Menko; Liesbeth Claassen; Daniëlle Rm Timmermans
Journal:  Patient Prefer Adherence       Date:  2020-02-19       Impact factor: 2.711

4.  Nurse-led decision coaching by specialized nurses for healthy BRCA1/2 gene mutation carriers - adaptation and pilot testing of a curriculum for nurses: a qualitative study.

Authors:  Birte Berger-Höger; Frank Vitinius; Hannah Fischer; Karolina Beifus; Juliane Köberlein-Neu; Anna Isselhard; Maren Töpper; Regina Wiedemann; Kerstin Rhiem; Rita Schmutzler; Stephanie Stock; Anke Steckelberg
Journal:  BMC Nurs       Date:  2022-02-10

5.  What Causes Cancer in Women with a gBRCA Pathogenic Variant? Counselees' Causal Attributions and Associations with Perceived Control.

Authors:  Friederike Kendel; Katharina Klein; Stephen Schüürhuis; Laura Besch; Markus A Feufel; Dorothee Speiser
Journal:  Genes (Basel)       Date:  2022-08-06       Impact factor: 4.141

6.  Making Sense of a Health Threat: Illness Representations, Coping, and Psychological Distress among BRCA1/2 Mutation Carriers.

Authors:  Hannah Brand; Dorothee Speiser; Laura Besch; Julia Roseman; Friederike Kendel
Journal:  Genes (Basel)       Date:  2021-05-14       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.